TRASTUREL 375MG ING

About

Trastuzumab, known as Trasturel, is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a proto-oncogene that, when overexpressed, plays a critical role in the development and progression of certain aggressive cancers, particularly breast and gastric cancers. By binding to HER2, trastuzumab inhibits the proliferation of tumor cells that overexpress HER2, mediates antibody-dependent cell-mediated cytotoxicity (ADCC), and prevents HER2 cleavage.

This targeted action makes Trasturel an effective therapy for HER2-positive malignancies, either as a monotherapy or in combination with chemotherapy. It significantly improves patient outcomes by slowing disease progression, reducing the risk of recurrence, and increasing survival rates. Trasturel is administered intravenously, providing a precise and powerful approach to combat HER2-driven cancers by directly interfering with the signaling pathways essential for tumor growth and survival.

Uses

• HER2-positive Breast Cancer (adjuvant, metastatic)
• HER2-positive Metastatic Gastric Cancer
• HER2-positive Gastroesophageal Junction Adenocarcinoma
• HER2-positive Esophageal Adenocarcinoma (off-label)

Directions For Use

Administer intravenously under the supervision of a healthcare professional, typically as an infusion. Dosage and frequency are determined by the specific cancer and patient characteristics.

Benefits

• Targets HER2-positive cancer cells specifically
• Slows tumor growth and progression
• Improves overall survival rates
• Reduces risk of cancer recurrence
• Can be used in combination with chemotherapy
• Offers a personalized treatment approach

Side Effects

• Infusion-related reactions (fever, chills, nausea)
• Cardiotoxicity (decreased left ventricular ejection fraction)
• Diarrhea
• Fatigue
• Headache
• Rash
• Anemia
• Neutropenia
• Myalgia
• Cough
• Dyspnea
• Peripheral edema

Safety Measures

• Alcohol - No direct interaction, but alcohol consumption should be discussed with a doctor, especially during cancer treatment, due to potential systemic effects.
• Pregnancy - Contraindicated due to potential for fetal harm, including oligohydramnios and pulmonary hypoplasia. Use effective contraception.
• Breastfeeding - Not recommended; discontinue breastfeeding during treatment and for a period after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with severe hepatic impairment; monitor liver function tests regularly during treatment.
• Kidney - No specific dose adjustment required for renal impairment; monitor renal function if co-administered with nephrotoxic agents.
• Lung - Use with caution in patients with pre-existing pulmonary conditions due to potential for pulmonary toxicity and dyspnea.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.